First AD

Second AD

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

Importance of Treating Anemia in MDS

Myeloproliferative Neoplasms

INC-22-OSD1258 - /clinical/myeloproliferative-neoplasms

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Yale Cancer Center

The Importance of Treating Anemia in MDS

Dissecting the Current Treatment Landscape in MDS

Optimal Goals for Anemia and Transfusion Independence in MDS

Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

Other Potential Roles for Luspatercept in MDS And Beyond

 Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

The Potential of Oral HMAs in MDS